A double-blind trial compared caspofungin with amphotericin B for the treatment of invasive candidiasis. The study enrolled 239 patients with clinical evidence of candida infection and a positive culture. Patients were stratified based on disease severity and neutropenia status and randomly assigned to receive either caspofungin or amphotericin B. The modified intention-to-treat analysis showed that caspofungin was as effective as amphotericin B, with 73.4% of patients in the caspofungin group and 61.7% in the amphotericin B group achieving successful outcomes. In an analysis of patients meeting prespecified criteria, caspofungin was superior, with 80.7% of patients showing favorable responses compared to 64.9% in the amphotericin B group. Caspofungin was equally effective as amphotericin B in patients with candidemia. There were significantly fewer drug-related adverse events in the caspofungin group. Caspofungin was at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia. The study was conducted between November 1997 and June 2001 at 56 institutions in 20 countries. Patients were eligible if they were over 18 years old and had one or more positive candida cultures within four days. Patients with certain infections were excluded. The study design included randomization, blinding, and a double-dummy technique to maintain blinding. Patients received antifungal therapy for 14 days after the most recent positive candida culture. The primary outcome was the end of intravenous therapy. The study also evaluated safety, including nephrotoxicity and drug-related adverse events. The results showed that caspofungin was as effective as amphotericin B in treating invasive candidiasis and candidemia, with fewer adverse events. The study was supported by grants from Merck. The authors had access to all study data and were responsible for the analysis and manuscript preparation. The study concluded that caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and candidemia.A double-blind trial compared caspofungin with amphotericin B for the treatment of invasive candidiasis. The study enrolled 239 patients with clinical evidence of candida infection and a positive culture. Patients were stratified based on disease severity and neutropenia status and randomly assigned to receive either caspofungin or amphotericin B. The modified intention-to-treat analysis showed that caspofungin was as effective as amphotericin B, with 73.4% of patients in the caspofungin group and 61.7% in the amphotericin B group achieving successful outcomes. In an analysis of patients meeting prespecified criteria, caspofungin was superior, with 80.7% of patients showing favorable responses compared to 64.9% in the amphotericin B group. Caspofungin was equally effective as amphotericin B in patients with candidemia. There were significantly fewer drug-related adverse events in the caspofungin group. Caspofungin was at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia. The study was conducted between November 1997 and June 2001 at 56 institutions in 20 countries. Patients were eligible if they were over 18 years old and had one or more positive candida cultures within four days. Patients with certain infections were excluded. The study design included randomization, blinding, and a double-dummy technique to maintain blinding. Patients received antifungal therapy for 14 days after the most recent positive candida culture. The primary outcome was the end of intravenous therapy. The study also evaluated safety, including nephrotoxicity and drug-related adverse events. The results showed that caspofungin was as effective as amphotericin B in treating invasive candidiasis and candidemia, with fewer adverse events. The study was supported by grants from Merck. The authors had access to all study data and were responsible for the analysis and manuscript preparation. The study concluded that caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and candidemia.